bioMérieux (Marcy l’Etoile, France) received the CE Mark for the firm’s third generation VIDAS immunoassay system. Many laboratories in the world run their automated immunoassays on a VIDAS system. All kind of biomolecules can be detected with this diagnostics platform, like infectious disease serology, but also cardiac, thyroid and cancer markers.
A Solid Phase Receptacle (SPR) is pre-coated with antigens or antibodies and serves as the pipetting device itself. At each stage of the reaction, it aspirates the reagents in and out. This original concept prevents any inter-reagent or inter-sample contamination during tests. It combines a traditional ELISA with fluorescent readouts.
Several CE and FDA approved panels are directly available for detection such as D-Dimer, procalcitonin, hepatitis A/B/C, HIV1/2 and more. The most important improvements are in the automation, pre-analytical section and quality control. Samples can be traced and software can be linked to the laboratory information system. Tests can be performed on demand or scheduled, individually or in series, 24 hours a day and seven days a week. Reagents already available for earlier VIDAS systems will also work on the VIDAS 3.
François Lacoste, Corporate Vice President, bioMérieux Immunoassay Unit was cited in the press release:
“Thanks to the VIDAS 3 CE marking, we are now able to provide biologists with an instrument that combines innovative technology and over 20 years of expertise acquired with the previous generations of our immunoassay platforms, VIDAS and mini VIDAS. With the launch of VIDAS 3, today bioMérieux expresses its medical vision by developing new solutions to improve people’s health. With this in mind, we will continue to seek regulatory approval in other countries, particularly the United States and China. Our ambition is to commercialize VIDAS 3 worldwide, so that this innovation will be available to as many laboratories as possible.”